Association between excess body weight and adverse effects using real body weight-based teprotumumab dosing in thyroid eye disease

PURPOSE: Monoclonal antibody therapies are often dosed using real body weight (RBW) to theoretically minimize inter-patient variability in drug distribution and elimination. However, pharmacokinetic modeling suggests that monoclonal antibodies primarily distribute to plasma and extracellular fluid compartments, which increase less than proportionally with excess body weight. Intravenous teprotumumab is currently administered using RBW-based dosing, but the impact of deviations from ideal body weight (IBW) on treatment response or adverse effects remains unclear. METHODS: A retrospective cohort of 95 patients treated with teprotumumab for Thyroid Eye Disease (TED). AEs were graded with Common Terminology Criteria for Adverse Events (CTCAE); high-grade was defined as grade ≥2. An IBW multiple (IBWM) for each patient was derived from RBW/IBW. Proptosis improvement was the millimeters reduction in Hertel exophthalmometry of the worse eye. Associations with IBWM were assessed using logistic and linear regression adjusted for age and diabetes. RESULTS: Median IBWM was 1.30 (range 0.84-2.98). Grade ≥1 AEs occurred in 86.3% and grade ≥2 in 30.5%. Higher IBWM was associated with greater odds of grade ≥2 AEs (adjusted OR 7.0, 95% CI 1.6-30.8; p = 0.010) and grade ≥2 AEs excluding hyperglycemia (adjusted OR 5.3, 95% CI 1.4-24.3; p = 0.020), but not with proptosis improvement (β ≈ 0.08 mm; p = 0.89). No patient at or below ideal body weight (IBWM ≤ 1; n = 7) experienced a grade ≥2 AE. CONCLUSIONS: Higher RBW dose intensity was associated with more high-grade toxicity without greater proptosis benefit. These findings suggest that RBW dosing may expose overweight patients to increased toxicity and support investigation of alternative dosing strategies for teprotumumab.

Authors

Institutions

Publication Details

Journal
Orbit
Published
2026-11-17
DOI
https://doi.org/10.1080/01676830.2026.2763112
Primary Topic
Ophthalmology and Eye Disorders
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Association between excess body weight and adverse effects using real body weight-based teprotumumab dosing in thyroid eye disease

Drew Ashbery, Aurora Rodríguez, Nikita Lalwani, Natalie Hoesly et al.
1 links
Orbit
Ophthalmology and Eye Disorders
article

Association between excess body weight and adverse effects using real body weight-based teprotumumab dosing in thyroid eye disease

Drew Ashbery, Aurora Rodríguez, Nikita Lalwani, Natalie Hoesly, John Daniel Ng, Davin Carlton Ashraf, Elliot Cherkas
article en

Abstract

PURPOSE: Monoclonal antibody therapies are often dosed using real body weight (RBW) to theoretically minimize inter-patient variability in drug distribution and elimination. However, pharmacokinetic modeling suggests that monoclonal antibodies primarily distribute to plasma and extracellular fluid compartments, which increase less than proportionally with excess body weight. Intravenous teprotumumab is currently administered using RBW-based dosing, but the impact of deviations from ideal body weight (IBW) on treatment response or adverse effects remains unclear. METHODS: A retrospective cohort of 95 patients treated with teprotumumab for Thyroid Eye Disease (TED). AEs were graded with Common Terminology Criteria for Adverse Events (CTCAE); high-grade was defined as grade ≥2. An IBW multiple (IBWM) for each patient was derived from RBW/IBW. Proptosis improvement was the millimeters reduction in Hertel exophthalmometry of the worse eye. Associations with IBWM were assessed using logistic and linear regression adjusted for age and diabetes. RESULTS: Median IBWM was 1.30 (range 0.84-2.98). Grade ≥1 AEs occurred in 86.3% and grade ≥2 in 30.5%. Higher IBWM was associated with greater odds of grade ≥2 AEs (adjusted OR 7.0, 95% CI 1.6-30.8; p = 0.010) and grade ≥2 AEs excluding hyperglycemia (adjusted OR 5.3, 95% CI 1.4-24.3; p = 0.020), but not with proptosis improvement (β ≈ 0.08 mm; p = 0.89). No patient at or below ideal body weight (IBWM ≤ 1; n = 7) experienced a grade ≥2 AE. CONCLUSIONS: Higher RBW dose intensity was associated with more high-grade toxicity without greater proptosis benefit. These findings suggest that RBW dosing may expose overweight patients to increased toxicity and support investigation of alternative dosing strategies for teprotumumab.

Orbit
Oregon Health & Science University (US)
Research to Prevent Blindness, National Institutes of Health
Good health and well-being
Ophthalmology and Eye Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon